



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: July 7, 2010

To: Primary Clinical Research Associates

From: Sara Braun
Protocol Development Coordinator

Re: N078D, Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT)
Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

With the distribution of Addenda 4 and 5 dated June 25, 2010, the Step 2 Eligibility Checklist was updated indicating that Addendum 5 had to be IRB approved prior to enrolling additional patients. This was incorrect. The Pre-Reg Eligibility Checklist should have been updated instead. This has now been corrected. Please begin using the Pre-Reg checklist which is dated June 25, 2010. The February 5, 2010 Eligibility Checklist will be the version that is in effect.

We apologize for any confusion this may have caused. If you have any questions, please feel free to contact me.

Enclosure